| Brian P Cunningham, MD | |
|
9 Church St, Arlington, VT 05250-0061 | |
| (802) 375-6566 | |
| (802) 375-6828 |
| Full Name | Brian P Cunningham |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 9 Church St, Arlington, Vermont |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821013244 | NPI | - | NPPES |
| 110099936 | Other | VT | RAILROAD MEDICARE |
| OX1788 | Other | PTAN | |
| 0007997 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 042-0006211 (Vermont) | Secondary |
| 207R00000X | Internal Medicine | 0420006211 (Vermont) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Brian P Cunningham, MD Po Box 61, Arlington, VT 05250-0061 Ph: (802) 375-6566 | Brian P Cunningham, MD 9 Church St, Arlington, VT 05250-0061 Ph: (802) 375-6566 |
News Archive
Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).
A recent finding by researchers at the BC Cancer Research Institute and the University of British Columbia may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.
Grip strength in the dominant hand and fat-free body mass (made mostly of muscle) increased when children with Duchenne muscular dystrophy (DMD) took the dietary supplement creatine at a dose of 0.1 grams per kilogram of body weight per day for four months.
Fluxion Biosciences, Inc. announced today that a research team from Fred Hutchinson Cancer Center has won the 2010 BioFlux Innovation Award competition. Laura Sycuro, Ph.D., a post-doctoral research fellow in the lab of David Fredricks, M.D., authored the winning submission which focuses on screening and characterizing bacterial strains involved in biofilm-related infections known to affect women's reproductive health.
A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex - a genetic disease characterized by benign tumors on multiple organ systems.
› Verified 1 days ago